The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Alendronate May Provide Cardiovascular Benefits; Plus FDA Approves Subcutaneous Tocilizumab

Alendronate May Provide Cardiovascular Benefits; Plus FDA Approves Subcutaneous Tocilizumab

May 28, 2018 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

New research has linked alendronate to reduced cardiovascular death in hip fracture patients. Also the U.S. Food and Drug Administration (FDA) approved subcutaneous tocilizumab for treating polyarticular juvenile idiopathic arthritis (PJIA) in patients age 2 and older.

You Might Also Like
  • FDA Approves Subcutaneous Tocilizumab for Ages 2–17
  • Rheumatology Drug Updates: Uncertain Future for Romosozumab, Plus FDA Approves Tocilizumab for GCA
  • European Commission Approves Subcutaneous Belimumab for SLE; FDA Safety Alert for Febuxostat
Also By This Author
  • FDA Update: Biosiomilar to Adalimumab Receives FDA Approval

Alendronate May Benefit the Heart
In a recent study, alendronate was linked to a reduced risk of cardiovascular death, myocardial infarction and stroke in hip fracture patients.1 These reductions occurred within 10 years after the hip fracture.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The study enrolled 34,991 patients with new hip fractures from 2005–2013 and followed them until late 2016. Of these patients, 13% received osteoporosis treatment during follow-up.

Alendronate use was associated with a 67% lower risk of one-year cardiovascular death and a 45% lower risk of myocardial infarction. Additionally, alendronate use was associated with an 18% reduced risk of stoke within five years and a 17% reduced risk of stroke within 10 years.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

FDA Approves Tocilizumab for Juvenile Arthritis
On May 14, the FDA approved the subcutaneous formulation of tocilizumab (Actemra) for treating active polyarticular juvenile idiopathic arthritis (PJIA) in patients age 2 and older. Tocilizumab can be given as monotherapy or in combination with methotrexate in patients with PJIA. In 2013, tocilizumab was approved for these patients, but in only an intravenous formulation.

JIA affects approximately 100 in every 100,000 children, 30% of whom have PJIA. This approval is based on data from the JIGSAW-117 study. This 52-week, open-label, multicenter, Phase 1b pharmacokinetic/pharmacodynamic bridging study was designed to determine the appropriate dosing regimens of subcutaneous tocilizumab for a range of children’s body weights.

Fifty-two PJIA patients, ranging in age from 1–17 years old, were enrolled in the study. Previously, these patients had inadequate responses or were intolerant to methotrexate. Patients could be tocilizumab naive or receiving intravenous tocilizumab with adequate disease control. Patients were given doses based on body weight: PJIA patients weighing less than 30 kg received 162 mg tocilizumab every three weeks, and PJIA patients weighing more than 30 kg received 162 mg tocilizumab every two weeks. Model-computed pharmacokinetic/pharmacodynamic parameters and safety were assessed.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The safety profile was similar to intravenous tocilizumab. However, patients using subcutaneous tocilizumab had more injection site reactions and neutropenia. Injection site reactions were reported in 29% of patients, but were mild in severity, none requiring treatment withdrawal or dose interruption. A decrease in neutrophil counts below 1×109/L occurred in 15% of patients and was more frequently observed in the patients weighing less than 30 kg (26%) compared with patients who weighed 30 kg or more (4%).

No new safety signals were identified.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Staff. Osteoporosis drug may benefit heart health. FirstWord Pharma. 2018 May 13.
  2. Genentech Inc. News release: FDA approves subcutaneous formulation of Actemra for use in active polyarticular juvenile idiopathic arthritis (PJIA), a rare form of juvenile arthritis. 2018 May 14.

Pages: 1 2 | Multi-Page

Filed Under: Drug Updates Tagged With: alendronate, cardiovascular, FDA, Fractures, hip fracture, Juvenile Arthritis (JIA), polyarticular juvenile idiopathic arthritis, tocilizumab, U.S. Food and Drug Administration (FDA)

You Might Also Like:
  • FDA Approves Subcutaneous Tocilizumab for Ages 2–17
  • Rheumatology Drug Updates: Uncertain Future for Romosozumab, Plus FDA Approves Tocilizumab for GCA
  • European Commission Approves Subcutaneous Belimumab for SLE; FDA Safety Alert for Febuxostat
  • Upadacitinib Monotherapy Proves Promising; Plus FDA Approves Tocilizumab Autoinjector

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.